KR20240110816A - 실로사이빈을 이용한 치료 저항성 우울증의 치료 - Google Patents
실로사이빈을 이용한 치료 저항성 우울증의 치료 Download PDFInfo
- Publication number
- KR20240110816A KR20240110816A KR1020247017950A KR20247017950A KR20240110816A KR 20240110816 A KR20240110816 A KR 20240110816A KR 1020247017950 A KR1020247017950 A KR 1020247017950A KR 20247017950 A KR20247017950 A KR 20247017950A KR 20240110816 A KR20240110816 A KR 20240110816A
- Authority
- KR
- South Korea
- Prior art keywords
- psilocybin
- dose
- subject
- weeks
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277407P | 2021-11-09 | 2021-11-09 | |
| US63/277,407 | 2021-11-09 | ||
| US202163284973P | 2021-12-01 | 2021-12-01 | |
| US63/284,973 | 2021-12-01 | ||
| PCT/US2022/048713 WO2023086252A1 (en) | 2021-11-09 | 2022-11-02 | Treatment of treatment resistant depression with psilocybin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240110816A true KR20240110816A (ko) | 2024-07-16 |
Family
ID=84799979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247017950A Pending KR20240110816A (ko) | 2021-11-09 | 2022-11-02 | 실로사이빈을 이용한 치료 저항성 우울증의 치료 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250000881A1 (https=) |
| EP (1) | EP4429671A1 (https=) |
| JP (1) | JP2024543379A (https=) |
| KR (1) | KR20240110816A (https=) |
| AU (1) | AU2022387053A1 (https=) |
| CA (1) | CA3237885A1 (https=) |
| MX (1) | MX2024005632A (https=) |
| WO (1) | WO2023086252A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) * | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| GB2588505B (en) * | 2017-10-09 | 2022-08-03 | Compass Pathfinder Ltd | Preparation of psilocybin |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
-
2022
- 2022-11-02 WO PCT/US2022/048713 patent/WO2023086252A1/en not_active Ceased
- 2022-11-02 MX MX2024005632A patent/MX2024005632A/es unknown
- 2022-11-02 US US18/703,950 patent/US20250000881A1/en active Pending
- 2022-11-02 JP JP2024527357A patent/JP2024543379A/ja active Pending
- 2022-11-02 CA CA3237885A patent/CA3237885A1/en active Pending
- 2022-11-02 EP EP22835920.4A patent/EP4429671A1/en active Pending
- 2022-11-02 AU AU2022387053A patent/AU2022387053A1/en active Pending
- 2022-11-02 KR KR1020247017950A patent/KR20240110816A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3237885A1 (en) | 2023-05-19 |
| EP4429671A1 (en) | 2024-09-18 |
| WO2023086252A1 (en) | 2023-05-19 |
| MX2024005632A (es) | 2024-07-29 |
| US20250000881A1 (en) | 2025-01-02 |
| JP2024543379A (ja) | 2024-11-21 |
| AU2022387053A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020259406B2 (en) | Treatment of depression and other various disorders with psilocybin | |
| KR20240110816A (ko) | 실로사이빈을 이용한 치료 저항성 우울증의 치료 | |
| KR20240122455A (ko) | 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제 | |
| TW201242600A (en) | Treatment of cognitive dysfunction in schizophrenia | |
| CN118488843A (zh) | 用赛洛西宾治疗难治性抑郁症 | |
| HK40068334A (en) | Treatment of depression and other various disorders with psilocybin | |
| HK40068314A (en) | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |